Bicara Therapeutics (NASDAQ:BCAX) Hits New 1-Year Low – Should You Sell?

Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) hit a new 52-week low on Tuesday . The stock traded as low as $11.43 and last traded at $11.65, with a volume of 251118 shares. The stock had previously closed at $11.60.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. RODMAN&RENSHAW upgraded Bicara Therapeutics to a “strong-buy” rating in a report on Tuesday, November 5th. Cantor Fitzgerald initiated coverage on shares of Bicara Therapeutics in a research note on Tuesday, October 8th. They issued an “overweight” rating for the company. TD Cowen initiated coverage on shares of Bicara Therapeutics in a research note on Tuesday, October 8th. They set a “buy” rating on the stock. Stifel Nicolaus initiated coverage on shares of Bicara Therapeutics in a report on Tuesday, October 8th. They set a “buy” rating and a $47.00 price target on the stock. Finally, Morgan Stanley assumed coverage on shares of Bicara Therapeutics in a report on Tuesday, October 8th. They issued an “overweight” rating and a $35.00 price objective for the company. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $43.75.

Bicara Therapeutics Trading Down 1.8 %

The firm’s 50-day moving average is $16.65.

Bicara Therapeutics (NASDAQ:BCAX) last announced its earnings results on Tuesday, November 12th. The company reported ($1.60) EPS for the quarter, missing the consensus estimate of ($0.46) by ($1.14). On average, equities analysts anticipate that Bicara Therapeutics Inc. will post -2.59 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Bicara Therapeutics

A number of institutional investors have recently made changes to their positions in BCAX. Spire Wealth Management acquired a new stake in Bicara Therapeutics in the 4th quarter valued at approximately $31,000. SG Americas Securities LLC bought a new stake in shares of Bicara Therapeutics in the fourth quarter valued at approximately $147,000. Cinctive Capital Management LP acquired a new stake in shares of Bicara Therapeutics in the third quarter worth $229,000. Barclays PLC bought a new position in Bicara Therapeutics during the third quarter worth $255,000. Finally, Jane Street Group LLC acquired a new position in Bicara Therapeutics during the 3rd quarter valued at $309,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.